Novartis AG is a Swiss-based healthcare company that drives innovation in the research, development, manufacturing, and marketing of a wide range of healthcare products globally. The company's primary focus is on creating prescription medicines that cater to the needs of patients and physicians worldwide.
One of the key areas of focus for Novartis is oncology, where they have developed cutting-edge treatments such as Pluvicto, a targeted therapy for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. Additionally, they offer Lutathera, a prescription medicine used to treat gastroenteropancreatic neuroendocrine tumors in adults and children aged 12 years and older.
Novartis has a diversified therapeutic portfolio that spans across several areas, including cardiovascular, renal and metabolic, immunology, neuroscience, and ophthalmology, as well as hematology. This broad range of therapeutic areas enables the company to address various unmet medical needs and improve patient outcomes.
The company has also established strategic partnerships to accelerate innovation and expand its product offerings. For instance, Novartis has a license and collaboration agreement with Alnylam Pharmaceuticals to develop and commercialize inclisiran, a novel therapy designed to reduce LDL cholesterol. Furthermore, they have partnered with Dawn Health to develop and commercialize Ekiva, a digital solution aimed at improving the lives of people living with Paroxysmal Nocturnal Hemoglobinuria.
Founded in 1996, Novartis AG is headquartered in Basel, Switzerland, and has established itself as a leader in the global healthcare industry. With a strong commitment to innovation and patient-centricity, the company continues to drive progress in the development of new treatments and therapies.
For more information about Novartis AG, please visit their official website at https://www.novartis.com.